Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection

Vaccine. 2012 Jan 11;30(3):626-36. doi: 10.1016/j.vaccine.2011.11.017. Epub 2011 Nov 23.

Abstract

Achieving broad-spectrum immunity against emerging zoonotic viruses such as avian influenza H5N1 and other possible pandemic viruses will require generation of cross-protective immune responses. Strong antibody responses generated against the H5HA protein are protective, however, antigenic variation between diverging isolates can interfere with virus neutralization. The current study investigates co-administration of an H5 HA DNA vaccine with other variable and conserved influenza antigens (NA, NP, and M2). All antigens were derived from the A/Hanoi/30408/2005 (H5N1) virus and the contribution towards overall protection and immune activation was assessed against lethal homologous and heterologous challenges. An (HA+NA) combination afforded the best protection against homologous challenge and (HA+NP) was comparable to HA alone against heterologous A/Hong Kong/483/1997 challenge. Interestingly, combining all four H5 antigens at a single site did not improve protection against matched challenge and unexpectedly reduced survival by 30% against a heterologous challenge. Survival was also significantly decreased against heterologous challenge following combination of (HA+NP) with an unrelated antigen. Although there were no significant changes in antibody titres, significantly lower T-cell responses were detected against all antigens except HA in each combination. Co-administration of the vaccines at different injection sites restored T-cell responses but did not improve overall protection. Similar observations were also recorded following combination of HA and NP antigens using two different adenovirus-based backbones. Overall, the data suggest that co-administering certain H5N1 antigens offer better or comparable protection to HA alone, however, combining extra antigens may be unnecessary and lead to unfavourable immune responses.

MeSH terms

  • Animals
  • Antibodies, Viral / blood*
  • Antigens, Viral / genetics
  • Antigens, Viral / immunology*
  • Disease Models, Animal
  • Hemagglutinin Glycoproteins, Influenza Virus / genetics
  • Hemagglutinin Glycoproteins, Influenza Virus / immunology
  • Influenza A Virus, H5N1 Subtype / genetics
  • Influenza A Virus, H5N1 Subtype / immunology*
  • Influenza Vaccines / administration & dosage*
  • Influenza Vaccines / immunology*
  • Mice
  • Mice, Inbred BALB C
  • Neuraminidase / genetics
  • Neuraminidase / immunology
  • Nucleocapsid Proteins
  • Orthomyxoviridae Infections / immunology
  • Orthomyxoviridae Infections / prevention & control
  • RNA-Binding Proteins / genetics
  • RNA-Binding Proteins / immunology
  • Survival Analysis
  • T-Lymphocytes / immunology
  • Vaccines, DNA / administration & dosage*
  • Vaccines, DNA / immunology*
  • Viral Core Proteins / genetics
  • Viral Core Proteins / immunology
  • Viral Matrix Proteins / genetics
  • Viral Matrix Proteins / immunology
  • Viral Proteins / genetics
  • Viral Proteins / immunology

Substances

  • Antibodies, Viral
  • Antigens, Viral
  • Hemagglutinin Glycoproteins, Influenza Virus
  • Influenza Vaccines
  • M2 protein, Influenza A virus
  • NP protein, Influenza A virus
  • Nucleocapsid Proteins
  • RNA-Binding Proteins
  • Vaccines, DNA
  • Viral Core Proteins
  • Viral Matrix Proteins
  • Viral Proteins
  • hemagglutinin, avian influenza A virus
  • NA protein, influenza A virus
  • Neuraminidase